BACKGROUND: ETV6-PDGFRB (also called TEL-PDGFRB) and FIP1L1-PDGFRA are receptor-tyrosine kinase fusion genes that cause chronic myeloid malignancies associated with hypereosinophilia. The aim of this work was to gain insight into the mechanisms whereby fusion genes affect human hematopoietic cells and in particular the eosinophil lineage. DESIGN AND METHODS: We introduced ETV6-PDGFRB and FIP1L1-PDGFRA into human CD34(+) hematopoietic progenitor and stem cells isolated from umbilical cord blood. RESULTS: Cells transduced with these oncogenes formed hematopoietic colonies even in the absence of cytokines. Both oncogenes also stimulated the proliferation of cells in liquid culture and their differentiation into eosinophils. This model thus recapitulated key features of the myeloid neoplasms induced by ETV6-PDGFRB and FIP1L1-PDGFRA. We next showed that both fusion genes activated the transcription factors STAT1, STAT3, STAT5 and nuclear factor-κB. Phosphatidylinositol-3 kinase inhibition blocked nuclear factor-κB activation in transduced progenitor cells and patients' cells. Nuclear factor-κB was also activated in the human FIP1L1-PDGFRA-positive leukemia cell line EOL1, the proliferation of which was blocked by bortezomib and the IκB kinase inhibitor BMS-345541. A mutant IκB that prevents nuclear translocation of nuclear factor-κB inhibited cell growth and the expression of eosinophil markers, such as the interleukin-5 receptor and eosinophil peroxidase, in progenitors transduced with ETV6-PDGFRB. In addition, several potential regulators of this process, including HES6, MYC and FOXO3 were identified using expression microarrays. CONCLUSIONS: We show that human CD34(+) cells expressing PDGFR fusion oncogenes proliferate autonomously and differentiate towards the eosinophil lineage in a process that requires nuclear factor-κB. These results suggest new treatment possibilities for imatinib-resistant myeloid neoplasms associated with PDGFR mutations.
BACKGROUND:ETV6-PDGFRB (also called TEL-PDGFRB) and FIP1L1-PDGFRA are receptor-tyrosine kinase fusion genes that cause chronic myeloid malignancies associated with hypereosinophilia. The aim of this work was to gain insight into the mechanisms whereby fusion genes affect human hematopoietic cells and in particular the eosinophil lineage. DESIGN AND METHODS: We introduced ETV6-PDGFRB and FIP1L1-PDGFRA into humanCD34(+) hematopoietic progenitor and stem cells isolated from umbilical cord blood. RESULTS: Cells transduced with these oncogenes formed hematopoietic colonies even in the absence of cytokines. Both oncogenes also stimulated the proliferation of cells in liquid culture and their differentiation into eosinophils. This model thus recapitulated key features of the myeloid neoplasms induced by ETV6-PDGFRB and FIP1L1-PDGFRA. We next showed that both fusion genes activated the transcription factors STAT1, STAT3, STAT5 and nuclear factor-κB. Phosphatidylinositol-3 kinase inhibition blocked nuclear factor-κB activation in transduced progenitor cells and patients' cells. Nuclear factor-κB was also activated in the humanFIP1L1-PDGFRA-positive leukemia cell line EOL1, the proliferation of which was blocked by bortezomib and the IκB kinase inhibitor BMS-345541. A mutant IκB that prevents nuclear translocation of nuclear factor-κB inhibited cell growth and the expression of eosinophil markers, such as the interleukin-5 receptor and eosinophil peroxidase, in progenitors transduced with ETV6-PDGFRB. In addition, several potential regulators of this process, including HES6, MYC and FOXO3 were identified using expression microarrays. CONCLUSIONS: We show that humanCD34(+) cells expressing PDGFR fusion oncogenes proliferate autonomously and differentiate towards the eosinophil lineage in a process that requires nuclear factor-κB. These results suggest new treatment possibilities for imatinib-resistant myeloid neoplasms associated with PDGFR mutations.
Authors: B Crescenzi; A Chase; R La Starza; D Beacci; V Rosti; A Gallì; G Specchia; M F Martelli; P Vandenberghe; J Cools; A V Jones; N C P Cross; P Marynen; C Mecucci Journal: Leukemia Date: 2007-01-11 Impact factor: 11.528
Authors: Yoshiyuki Yamada; Marc E Rothenberg; Andrew W Lee; Hiroko Saito Akei; Eric B Brandt; David A Williams; Jose A Cancelas Journal: Blood Date: 2006-01-17 Impact factor: 22.113
Authors: Aravind Subramanian; Pablo Tamayo; Vamsi K Mootha; Sayan Mukherjee; Benjamin L Ebert; Michael A Gillette; Amanda Paulovich; Scott L Pomeroy; Todd R Golub; Eric S Lander; Jill P Mesirov Journal: Proc Natl Acad Sci U S A Date: 2005-09-30 Impact factor: 11.205
Authors: Anders Kallin; Lene E Johannessen; Patrice D Cani; Catherine Y Marbehant; Ahmed Essaghir; Fabienne Foufelle; Pascal Ferré; Carl-Henrik Heldin; Nathalie M Delzenne; Jean-Baptiste Demoulin Journal: J Lipid Res Date: 2007-04-23 Impact factor: 5.922
Authors: S Burgstaller; S Kreil; K Waghorn; G Metzgeroth; C Preudhomme; K Zoi; H White; D Cilloni; C Zoi; F Brito-Babapulle; C Walz; A Reiter; N C P Cross Journal: Leukemia Date: 2007-10-04 Impact factor: 11.528
Authors: Laura A Noël; Florence A Arts; Carmen P Montano-Almendras; Luk Cox; Olga Gielen; Federica Toffalini; Catherine Y Marbehant; Jan Cools; Jean-Baptiste Demoulin Journal: Mol Oncol Date: 2014-02-17 Impact factor: 6.603
Authors: Ashley N Stouch; Rinat Zaynagetdinov; Whitney J Barham; Amanda M Stinnett; James C Slaughter; Fiona E Yull; Hal M Hoffman; Timothy S Blackwell; Lawrence S Prince Journal: J Immunol Date: 2014-06-30 Impact factor: 5.422